drug-eluting stents

Does a Combination of Diabetes and Acute Coronary Syndrome Change the Revascularization Strategy?

The results of the FREEDOM (Future Revascularization Evaluation in Patients With Diabetes Mellitus: Optimal Management of Multi-vessel Disease) trial have shown a lower rate of events in patients with diabetes and stable multivessel disease who were randomized to undergo myocardial revascularization surgery, compared to those who underwent angioplasty. Surgery even showed a mortality reduction that<a href="https://solaci.org/en/2018/01/22/does-a-combination-of-diabetes-and-acute-coronary-syndrome-change-the-revascularization-strategy/" title="Read more" >...</a>

Calidad de vida entre cirugía y angioplastia para tratar la enfermedad del tronco

Quality of Life Between Surgery and Angioplasty for the Treatment of Left Main Disease

In recent years, angioplasty with drug-eluting stents (DES) has emerged as an alternative to myocardial revascularization surgery in patients with left main coronary artery disease. Both European and American guidelines offer a Class&nbsp;IIa recommendation for left main coronary artery (LMCA) angioplasty in selected patients. The EXCEL (Evaluation of Xience Versus Coronary Artery Bypass Surgery for<a href="https://solaci.org/en/2018/01/11/quality-of-life-between-surgery-and-angioplasty-for-the-treatment-of-left-main-disease/" title="Read more" >...</a>

La ATC es una alternativa válida en el TCI

Coronary Angioplasty Is a Valid Alternative for Left Main Coronary Artery Disease

Courtesy of Dr. Carlos&nbsp;Fava. Severe left main coronary artery (LMCA) lesions have a bad prognosis in coronary disease. In that scenario, current guidelines recommend surgery as the treatment of choice. However, due to the current development of second-generation drug-eluting stents (DES) and greater operator expertise, left main coronary artery angioplasty appears as a valid alternative<a href="https://solaci.org/en/2018/01/05/coronary-angioplasty-is-a-valid-alternative-for-left-main-coronary-artery-disease/" title="Read more" >...</a>

ticagrelor-clopidogrel-compressor

Clopidogrel or Ticagrelor in Patients with Acute Coronary Syndrome Treated with New-Generation DES: CHANGE DAPT

Courtesy of Dr. Pablo Baglioni. This is a prospective observational study with a 1-year follow-up analyzing 2062 patients with acute coronary syndrome (ACS)&nbsp;who have been treated with coronary angioplasty using new-generation drug-eluting stents (DES). Patients were included between December 21, 2012 and August 25, 2015. On May, 2014, due to changes in international guidelines, clopidogrel<a href="https://solaci.org/en/2017/12/15/clopidogrel-or-ticagrelor-in-patients-with-acute-coronary-syndrome-treated-with-new-generation-des-change-dapt/" title="Read more" >...</a>

8 artículos sobre Oclusiones Crónicas Totales que no puede dejar de leer

6 articles on Total Chronic Occlusions that you can not stop reading

1)&nbsp;Radiation Exposure in Chronic Total Occlusions Even in the hands of experienced operators, rechanneling and&nbsp;angioplasty&nbsp;of a&nbsp;chronic total occlusion (CTO)&nbsp;results in patients and the whole cath lab team receiving high doses of radiation, according to this registry presented at the&nbsp;American Heart Association 2017 Scientific Sessions. Read more&nbsp; &nbsp; 2)&nbsp;Should We Begin to Use IVUS in CTO?<a href="https://solaci.org/en/2017/12/12/6-articles-on-total-chronic-occlusions-that-you-can-not-stop-reading/" title="Read more" >...</a>

DARE: los balones farmacológicos compiten con los DES para tratar la reestenosis intrastent

DARE: Drug-Coated Balloons Compete with DES for the Treatment of In-Stent Restenosis

Courtesy of the Brazilian Society of Hemodynamics and Interventional Cardiology (SBHCI). The SeQuent Please paclitaxel-coated balloon provides non-inferior angiographic results when compared with the Xience everolimus-eluting stent for the treatment of in-stent restenosis. At 6&nbsp;months, the minimal lumen diameter was 1.71&nbsp;mm in the drug-coated balloon arm and 1.74&nbsp;mm in the Xience arm, a difference that<a href="https://solaci.org/en/2017/11/01/dare-drug-coated-balloons-compete-with-des-for-the-treatment-of-in-stent-restenosis/" title="Read more" >...</a>

Las plataformas bioabsorbibles no deben ser elegidas por sobre los DES actuales

Bioresorbable Scaffolds Must Not Be Chosen Over Current DES

Although there are 4 approved bioresorbable scaffolds (BRS) in Europe, experts suggest that current drug-eluting stents (DES) are the best option for coronary angioplasty. These new guidelines jointly published by the European Society of Cardiology (ESC) and the Association of Percutaneous Cardiovascular Interventions (EAPCI) are an update on the use of BRS in clinical practice<a href="https://solaci.org/en/2017/10/19/bioresorbable-scaffolds-must-not-be-chosen-over-current-des/" title="Read more" >...</a>

Very Late Thrombosis in Bioresorbable Scaffolds

The presence of a metallic device interrupts normal laminar flow and creates an artery environment that favors thrombosis, leaving the vessel vulnerable to very late thrombosis. Dual antiplatelet therapy, a better implantation technique, and several improvements in new drug-eluting stents (DES) (thinner struts, and higher polymer stability and biocompatibility) have lowered significantly the incidence of<a href="https://solaci.org/en/2017/09/26/very-late-thrombosis-in-bioresorbable-scaffolds/" title="Read more" >...</a>

bioresorbable-vascular-scaffold

Polymer-Free DES Also Show Efficacy in Anticoagulated Patients with High Risk for Bleeding

Patients who receive chronic anticoagulation therapy and then undergo angioplasty are frequently discharged on a triple anti-thrombotic scheme that usually includes&nbsp;aspirin, clopidogrel, and warfarin. The optimal duration of this indication remains unclear, particularly for patients at high bleeding risk. According to expert consensus, patients receiving chronic anticoagulation may receive from 1 to 12&nbsp;months of dual<a href="https://solaci.org/en/2017/09/08/polymer-free-des-also-show-efficacy-in-anticoagulated-patients-with-high-risk-for-bleeding/" title="Read more" >...</a>

¿Debemos comenzar a utilizar IVUS en las CTO?

Should We Begin to Use IVUS in CTO?

Courtesy of Dr. Carlos&nbsp;Fava. Currently,&nbsp;chronic total occlusions&nbsp;(CTO)&nbsp;are one of the obstacles that&nbsp;coronary angioplasties must overcome, particularly with the development of&nbsp;drug-eluting stents (DES)&nbsp;and new devices and strategies for these challenging lesions. However, there is little information on the safety, efficacy, and real clinical benefit of implanting stents of over 60&nbsp;mm (known as full metal jackets, FMJ).<a href="https://solaci.org/en/2017/08/28/should-we-begin-to-use-ivus-in-cto/" title="Read more" >...</a>

Top